Skip to main content

Market Overview

Gilead Hits New 52-Week Low; Here Are Two Reasons Why


Shares of Gilead Sciences, Inc. (NASDAQ: GILD) lost more than 5 percent on Friday and hit a new 52-week low of $82.41 after the company announced a change to its senior leadership.

Effective March 10, 2016, Gilead's current Chairman and CEO John Martin will assume the role of Executive Chairman of the company. Replacing Martin will be John Milligan, the company's current President and Chief Operating Officer.

Martin joined Gilead in 1990 and was named CEO in 1996 and Chairman of the Board in 2008. Milligan also joined the company in 1990 and was named Chief Operating Officer in 2007 and President in 2008.

Investors and traders were also reacting to Merck & Co., Inc. (NYSE: MRK)'s announcement that the FDA approved its Hep C drug named ZEPATIER. According to Firece Biotech, Merck's new drug will compete "toe-to-toe" with Gilead's Hep C "goliath," Sovaldi.


Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: Gilead john martinNews Health Care Management Intraday Update Movers General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at